切换至 "中华医学电子期刊资源库"
高级检索
中华肝脏外科手术学电子杂志

中华肝脏外科手术学电子杂志 ›› 2015, Vol. 04 ›› Issue (01) : 50 -52. doi: 10.3877/cma.j.issn.2095-3232.2015.01.014

所属专题： 文献；

基础研究

siRNA沉默HCCR-2基因抑制卵巢癌肝转移的实验研究
王晶1, 梁建明2, 刘安琪3, 陈文捷4, 何勉1,†()   
  1. 1. 510080　广州，中山大学附属第一医院妇产科
    2. 510080　广州，中山大学附属第一医院检验科
    3. 510630　广州，中山大学附属第三医院科研科
    4. 510630　广州，中山大学附属第三医院肝脏病实验室
  • 收稿日期:2014-10-19 出版日期:2015-02-10
  • 通信作者: 何勉
  • 基金资助:
    国家自然科学基金(81302550，81301331); 广东省自然科学基金(S2013010015552)

Inhibition of HCCR-2 gene expression by siRNA suppresses liver metastasis of ovarian cancer

Jing Wang1, Jianming Liang2, Anqi Liu3, Wenjie Chen4, Mian He1,†()   

  1. 1. Department of Obstetrics and Gynecology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
    2. Department of Laboratory, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou 510080, China
    3. Research Service office, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
    4. Laboratory of Liver Disease, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
  • Received:2014-10-19 Published:2015-02-10
  • Corresponding author: Mian He
  • About author:
    Corresponding author: He Mian, Email:
全文 ( ) 下载PDF ( ) 导出引用
引用本文：

王晶, 梁建明, 刘安琪, 陈文捷, 何勉. siRNA沉默HCCR-2基因抑制卵巢癌肝转移的实验研究[J]. 中华肝脏外科手术学电子杂志, 2015, 04(01): 50-52.

Jing Wang, Jianming Liang, Anqi Liu, Wenjie Chen, Mian He. Inhibition of HCCR-2 gene expression by siRNA suppresses liver metastasis of ovarian cancer[J]. Chinese Journal of Hepatic Surgery(Electronic Edition), 2015, 04(01): 50-52.

目的

探讨siRNA抑制人宫颈癌基因2（HCCR-2）表达对卵巢癌肝转移能力的影响。

方法

HCCR-2-siRNA慢病毒表达载体及空载体对照质粒感染人卵巢癌高转移细胞HO-8910PM，建立小干扰（SI）组和空白对照（NC）组。采用Western blot检测HCCR-2蛋白表达。采用Transwell法检测癌细胞侵袭能力，卵巢癌肝转移模型裸鼠观察癌细胞转移能力。两组实验数据比较采用t检验，率的比较采用χ2检验。

结果

SI组细胞HCCR-2蛋白的平均相对表达量为0.16±0.02，较NC组的0.86±0.05明显减少（t=-8.06，P<0.05）。SI组的穿膜细胞数为（58±3）个，较NC组的（262±19）个明显减少（t=-37.77，P<0.05）。SI组的肝转移癌发生率2/6，较NC组的6/6明显降低（P<0.05）；SI组成瘤数量为（1.3±0.2）个，较NC组的（9.4±0.8）个明显减少（t=-10.25，P<0.05）。

结论

siRNA沉默抑制HCCR-2基因表达可降低卵巢癌细胞的侵袭和肝转移能力。

关键词: 肿瘤，未知原发灶, 肝肿瘤, 卵巢肿瘤, 人宫颈癌基因2
Objective

To investigate the impact of human cervical cancer oncogene-2 (HCCR-2) inhibited by small interference RNA (siRNA) on the liver metastatic potential of ovarian cancer.

Methods

High metastatic ability human ovarian cancer cell line HO-8910PM was infected using HCCR-2-siRNA lentiviral expression vector and empty negative control vector to establish small interference (SI) group and negative control (NC) group. The expression of HCCR-2 protein in two groups was detected by Western blot assay. Transwell assay was used to define the cell invasion ability. Liver metastases model of ovarian cancer was established to detect the cell metastatic ability. The data between two groups were compared using t test, and the rates were compared using Chi-square test.

Results

The average relative expression of HCCR-2 protein in SI group (0.16±0.02) significantly decreased compared with that in NC group (0.86±0.05) (t=-8.06, P<0.05). The membrane permeating cell count in SI group (58±3) was significantly less than that in NC group (262±19) (t=-37.77, P<0.05). The incidence of liver metastases in SI group (2/6) was significantly lower than that in NC group (6/6) (P<0.05). The number of metastases in SI group (1.3 ± 0.2) was significantly less than that in NC group (9.4 ± 0.8) (t = -10.25, P<0.05).

Conclusion

Inhibition of HCCR-2 gene expression by siRNA can reduce the invasion and liver metastatic potential of ovarian cancer cells.

Key words: Neoplasms, unknown primary, Liver neoplasms, Ovarian neoplasms, Human cervical cancer oncogene-2
[1]
Jirun P, Zhang G, Ha SA, et al. HCCR-1 for detecting small hepatocellular carcinoma latent in a cirrhotic liver: a prospective cohort study[J]. Gut, 2012, 61(10):1514-1515.
[2]
Ha SA, Kim HK, Yoo JA, et al. HCCRBP-3 induces tumorigenesis through direct interaction with HCCR-1 in human cancers[J]. Mol Carcinog, 2014, 53(1):30-37.
[3]
Lalmahomed ZS, Ayez N, van der Pool AE, et al. Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome?[J]. World J Surg, 2011, 35(3):656-661.
[4]
Kazaryan AM, Marangos IP, Rosok BI, et al. Laparoscopic resection of colorectal liver metastases: surgical and long-term oncologic outcome[J]. Ann Surg, 2010, 252(6):1005-1012.
[5]
Kim KH, Yoon YS, Yu CS, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases[J]. J Korean Surg Soc, 2011, 81(1):25-34.
[6]
Lermite E, Marzano E, Chereau E, et al. Surgical resection of liver metastases from breast cancer[J]. Surg Oncol, 2010, 19(4):e79-84.
[7]
Snoeren N, van Hooff SR, Adam R, et al. Exploring gene expression signatures for predicting disease free survival after resection of colorectal cancer liver metastases[J]. PLoS One, 2012, 7(11):e49442.
[8]
Li H, Yang W, Chen PW, et al. Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases[J]. Invest Ophthalmol Vis Sci, 2009, 50(12):5522-5528.
[9]
Qiao SS, Cui ZQ, Gong L, et al. Simultaneous measurements of serum AFP, GPC-3 and HCCR for diagnosing hepatocellular carcinoma[J]. Hepatogastroenterology, 2011, 58(110/111):1718-1724.
[10]
Ha SA, Kim HK, Yoo J, et al. Transdifferentiation-inducing HCCR-1 oncogene[J]. BMC Cell Biol, 2010(11):49.
[11]
Zhang G, Ha SA, Kim HK, et al. Combined analysis of AFP and HCCR-1 as an useful serological marker for small hepatocellular carcinoma: a prospective cohort study[J]. Dis Markers, 2012, 32(4):265-271.
[12]
Xu Z, Zhang Y, Jiang J, et al. Epidermal growth factor induces HCCR expression via PI3K/Akt/mTOR signaling in PANC-1 pancreatic cancer cells[J]. BMC Cancer, 2010, 10(1):161.
[13]
Ha SA, Lee YS, Shin SM, et al. Oncoprotein HCCR-1 expression in breast cancer is well correlated with known breast cancer prognostic factors including the HER2 overexpression, p53 mutation, and ER/PR status[J]. BMC Cancer, 2009, 9(1):51.
[1] 韩丹, 王婷, 肖欢, 朱丽容, 陈镜宇, 唐毅. 超声造影与增强CT对儿童肝脏良恶性病变诊断价值的对比分析[J]. 中华医学超声杂志（电子版）, 2023, 20(09): 939-944.
[2] 林昌盛, 战军, 肖雪. 上皮性卵巢癌患者诊疗中基因检测及分子靶向药物治疗[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 505-510.
[3] 李建美, 邓静娟, 杨倩. 两种术式联合治疗肝癌合并肝硬化门静脉高压的安全性及随访评价[J]. 中华普外科手术学杂志(电子版), 2024, 18(01): 41-44.
[4] 陈忠垚, 陈胜灯, 李秋. 不同手术时机对原发性肝癌自发破裂出血患者远期预后的影响[J]. 中华普外科手术学杂志(电子版), 2023, 17(05): 518-521.
[5] 杜锡林, 谭凯, 贺小军, 白亮亮, 赵瑶瑶. 肝细胞癌转化治疗方式[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 597-601.
[6] 崔佳琪, 吴迪, 陈海艳, 周惠敏, 顾元龙, 周光文, 杨军. TACE术后并发肝脓肿的临床诊治分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 688-693.
[7] 唐灿, 李向阳, 秦浩然, 李婧, 王天云, 柯阳, 朱红. 原发性肝脏神经内分泌肿瘤单中心12例诊治与疗效分析[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 674-680.
[8] 韩冰, 顾劲扬. 深度学习神经网络在肝癌诊疗中的研究及应用前景[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 480-485.
[9] 何传超, 肖治宇. 晚期肝癌综合治疗模式与策略[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 486-489.
[10] 王楚风, 蒋安. 原发性肝癌的分子诊断[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 499-503.
[11] 顾娇娇, 邹燕, 陈奕辰, 黄师菊, 张慧玲, 林楠. 基于简易营养评价精法评估肝癌患者出院后营养状况及其影响因素[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 534-539.
[12] 孟令展, 李虎, 俞鹏, 于燕宾, 曹李, 翟伟, 高远, 邵艳玲, 严锦, 朱震宇. ICG荧光染色在肝癌腹腔镜解剖性肝切除术中的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(05): 557-561.
[13] 赫嵘, 贾哲, 张珂, 李代京, 张萌, 蒋力. 基于PSM分析腹腔镜肝切除联合Hassab术治疗合并门静脉高压症肝癌疗效[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 376-383.
[14] 杨发才, 游川, 雷正清, 李伟男, 段安琪, 邱应和, 李敬东, 程张军. 肿瘤负荷评分联合淋巴结分期对肝内胆管细胞癌患者术后生存预测价值[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 389-394.
[15] 李映安, 晋云, 储心昀, 胡苹苹, 王峻峰. 混合现实技术在腹腔镜肝切除术中导航的应用[J]. 中华肝脏外科手术学电子杂志, 2023, 12(04): 401-406.
阅读次数
全文


摘要

版权所有 中华医学会 中华医学电子音像出版社有限责任公司  京ICP备14006079号-1  网络出版服务许可证：(署)网出证(京)字第075号